BCL2 and breast carcinoma: Experiments with resveratrol in MCF-7 breast cancer cells revealed that the polyphenol acts as an estrogen receptor agonist, but, at the same time, reduces the Bcl-2/Bax ratio implying that it is a candidate for hormone replacement therapy (HRT) [118].